(NASDAQ: OTLK) Outlook Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.98%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.26%.
Outlook Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast OTLK's revenue for 2024 to be $33,827,559, with the lowest OTLK revenue forecast at $33,827,559, and the highest OTLK revenue forecast at $33,827,559. On average, 4 Wall Street analysts forecast OTLK's revenue for 2025 to be $175,926,965, with the lowest OTLK revenue forecast at $113,547,053, and the highest OTLK revenue forecast at $257,136,763.
In 2026, OTLK is forecast to generate $1,255,309,980 in revenue, with the lowest revenue forecast at $1,163,857,291 and the highest revenue forecast at $1,351,919,597.